Copenhagen, 17 December 2010 – Today, NeuroSearch (NEUR) released the company’s financial calendar for 2011:
Financial calendar for 2011
| 10 March 2011 | Annual Report 2010 |
| 27 April 2011 | Annual General Meeting and first quarter 2011 report |
| 25 August 2011 | Second quarter 2011 report |
| 17 November 2011 | Third quarter 2011 report |
Patrik Dahlen
CEO
Contact persons:
Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations, telephone: +45 4460 8212 or +45 4017 5103
About NeuroSearch
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business is development of novel drugs to treat diseases of the central nervous system (CNS), and the pipeline comprises eight products in clinical development (Phase I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase III for the treatment of Huntington’s disease, and tesofensine ready for Phase III development as a new type of obesity treatment. NeuroSearch is also building commercial competences with a view to market Huntexil® through an in-house sales organisation.
NeuroSearch has a well-established drug discovery platform in the field of ion channels and monoamine transporters, ensuring the continuous production of novel pharmaceutical agents. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. Further, NeuroSearch has equity interests in a number of private companies in the Life Science industry.
